Multi-parametric assessment of the anti-angiogenic effects of liposomal glucocorticoids

Angiogenesis

Volumn 14, Issue 2, 2011, Pages 143-153

  Kluza, Ewelina ^a   Heisen, Marieke ^a   Schmid, Sophie ^a   Van Der Schaft, Daisy W J ^a   Schiffelers, Raymond M ^b   Storm, Gert ^b   Ter Haar Romeny, Bart M ^a   Strijkers, Gustav J ^a   Nicolay, Klaas ^a  

^a EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Anti angiogenic effects; DCE MRI; Glucocorticoids; Liposomes; Tumor associated inflammation

Indexed keywords

GADOLINIUM CHELATE; LIPOSOME; PREDNISOLONE 21 PHOSPHATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DRUG POTENCY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MELANOMA; MICROVASCULATURE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL PROLIFERATION; CELL SURVIVAL; CONTRAST MEDIA; DIFFUSION MAGNETIC RESONANCE IMAGING; GLUCOCORTICOIDS; LIPOSOMES; MICE; MICE, INBRED C57BL; MICROSCOPY, FLUORESCENCE; MICROVESSELS; NEOPLASMS; PREDNISOLONE;

ANIMALIA; MUS;

EID: 79959947588     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-010-9198-5     Document Type: Article

References (49)

1. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860-867. doi:10.1038/nature01322 (Pubitemid 36019639)
2. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436-444. doi:10.1038/nature07205
3. Schiffelers RM, de Visser KE (2009) Inflammation as target for pharmaceutical intervention in cancer. Curr Pharm Des 15(16):1822-1824
4. Mantovani G, Macciò A, Madeddu C, Serpe R, Antoni G, Massa E et al (2010) Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J Mol Med 88(1):85-92. doi:10.1007/s00109-009-0547-z
5. Debucquoy A, Roels S, Goethals L, Libbrecht L, Cutsem EV, Geboes K et al (2009) Double blind randomized phase II study with radiation + 5-fluorouracil ± celecoxib for resectable rectal cancer. Radiother Oncol 93(2):273-278. doi:10.1016/j.radonc.2009.08.006
6. Bhatt RS, Merchan J, Parker R, Wu HK, Zhang L, Seery V et al (2010) A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer 116(7):1751-1756. doi:10.1002/cncr.24902
7. Sooriakumaran P, Coley HM, Fox SB, Macanas-Pirard P, Lovell DP, Henderson A et al (2009) A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer. Anticancer Res 29(5):1483-1488
8. Folkman J, Langer R, Linhardt RJ, Haudenschild C, Taylor S (1983) Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 221(4612):719-725. doi:10.1126/science.6192498 (Pubitemid 13030626)
9. Penhaligon M, Camplejohn RS (1985) Combination heparin plus cortisone treatment of two transplanted tumors in C3H/He mice. J Natl Cancer Inst 74(4):869-873 (Pubitemid 15118244)
10. Schiffelers RM, Metselaar JM, Fens MHAM, Janssen APCA, Molema G, Storm G (2005) Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice. Neoplasia 7(2):118-127. doi:10.1593/neo.04340 (Pubitemid 40315989)
11. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51(4):691-743
12. Drummond DC, Noble CO, Hayes ME, Park JW, Kirpotin DB (2008) Pharmacokinetics and in vivo drug release rates in lipo-somal nanocarrier development. J Pharm Sci 97(11):4696-4740. doi:10.1002/jps.21358
13. Greish K (2010) Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol 624:25-37
14. Banciu M, Fens MHAM, Storm G, Schiffelers RM (2008) Antitumor activity and tumor localization of liposomal gluco-corticoids in B16 melanoma-bearing mice. J Control Release 127(2):131-136. doi:10.1016/j.jconrel.2008.01.008
15. Banciu M, Schiffelers RM, Fens MHAM, Metselaar JM, Storm G (2006) Anti-angiogenic effects of liposomal prednisolone phosphate on B16 melanoma in mice. J Control Release 113(1):1-8. doi:10.1016/j.jconrel.2006.03.019 (Pubitemid 43818165)
16. Banciu M, Metselaar JM, Schiffelers RM, Storm G (2008) Antitumor activity of liposomal prednisolone phosphate depends on the presence of functional tumor-associated macrophages in tumor tissue. Neoplasia 10(2):108-117. doi:10.1593/neo.07913 (Pubitemid 351240876)
17. Jackson A, O'Connor JPB, Parker GJM, Jayson GC (2007) Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 13(12):3449-3459. doi:10.1158/1078-0432.CCR- 07-0238 (Pubitemid 46955104)
18. O'Connor JPB, Jackson A, Parker GJM, Jayson GC (2007) DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 96(2):189-195. doi: 10.1038/sj.bjc.6603515 (Pubitemid 46160619)
19. Moffat BA, Hall DE, Stojanovska J, McConville PJ, Moody JB, Chenevert TL et al (2004) Diffusion imaging for evaluation of tumor therapies in preclinical animal models. MAGMA 17(3-6):249-259. doi:10.1007/s10334-004-0079-z (Pubitemid 40362308)
20. Carano RAD, Ross AL, Ross J, Williams SP, Koeppen H, Schwall RH et al (2004) Quantification of tumor tissue populations by multispectral analysis. Magn Reson Med 51(3):542-551. doi: 10.1002/mrm.10731 (Pubitemid 38298668)
21. Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324(1):1-8
22. Bertolini F, Mancuso P, Shaked Y, Kerbel RS (2007) Molecular and cellular biomarkers for angiogenesis in clinical oncology. Drug Discov Today 12(19-20):806-812. doi:10.1016/j.drudis. 2007.08.011 (Pubitemid 47539970)
23. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706):58-62. doi: 10.1126/science.1104819 (Pubitemid 40093472)
24. Metselaar JM, Wauben MHM, Wagenaar-Hilbers JPA, Boerman OC, Storm G (2003) Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating lipo-somes. Arthritis Rheum 48(7):2059-2066. doi:10.1002/art. 11140 (Pubitemid 36828702)
25. Rouser G, Fkeischer S, Yamamoto A (1970) Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 5(5):494-496
26. Stejskal E, Tanner J (1965) Spin diffusion measurements: spin echoes in the presence of a time-dependent field gradient. J Chem Phys 42(1):288
27. Kaufman L, Kramer DM, Crooks LE, Ortendahl DA (1989) Measuring signal-to-noise ratios in MR imaging. Radiology 173(1):265-267 (Pubitemid 19242443)
28. Medved M, Karczmar G, Yang C, Dignam J, Gajewski TF, Kindler H et al (2004) Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: variability and changes in tumor tissue over time. J Magn Reson Imag 20(1):122-128. doi:10.1002/jmri.20061 (Pubitemid 38857525)
29. Marzola P, Mocchegiani E, Nicolato E, Tibaldi A, Sbarbati A, Osculati F (1999) Chemical shift imaging at 4.7 tesla of thymus in young and old mice. J Magn Reson Imag 10(1):97-101 (Pubitemid 29336645)
30. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV et al (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imag 10(3):223-232 (Pubitemid 29463104)
31. Kovar DA, Lewis M, Karczmar GS (1998) A new method for imaging perfusion and contrast extraction fraction: input functions derived from reference tissues. J Magn Reson Imag 8(5):1126-1134 (Pubitemid 28481800)
32. Heisen M, Fan X, Buurman J, van Riel NAW, Karczmar GS, ter Haar Romeny BM (2010) The use of a reference tissue arterial input function with low temporal resolution DCE-MRI data. Phys Med Biol 55(16):4871-4883. doi:10.1088/0031-9155/ 55/16/016
33. Fan X, Medved M, River JN, Zamora M, Corot C, Robert P et al (2004) New model for analysis of dynamic contrast-enhanced MRI data distinguishes metastatic from nonmetastatic transplanted rodent prostate tumors. Magn Reson Med 51(3):487-494. doi:10.1002/mrm.10737 (Pubitemid 38298661)
34. Press WH, Teukolsky SA, Vetterling WT, Flannery BP (1996) Numerical recipes in Fortran 77: the art of scientific computing, 2nd edn. Cambridge University Press, New York
35. Szabó BK, Aspelin P, Wiberg MK, Boné B (2003) Dynamic MR imaging of the breast. Analysis of kinetic and morphologic diagnostic criteria. Acta Radiol 44(4):379-386
36. Furman-Haran E, Schechtman E, Kelcz F, Kirshenbaum K, Degani H (2005) Magnetic resonance imaging reveals functional diversity of the vasculature in benign and malignant breast lesions. Cancer 104(4):708-718. doi:10.1002/cncr. 21225 (Pubitemid 41113669)
37. de Lussanet QG, Backes WH, Griffioen AW, Padhani AR, Baeten CI, van Baardwijk A et al (2005) Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. Int J Radiat Oncol Biol Phys 63(5):1309-1315. doi:10.1016/j.ijrobp.2005.04.052 (Pubitemid 41628023)
38. Franchimont D (2004) Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies. Ann N Y Acad Sci 1024:124-137. doi:10.1196/annals.1321.009 (Pubitemid 38879597)
39. Coleman RE (1992) Glucocorticoids in cancer therapy. Biotherapy 4(1):37-44
40. Herr I, Pfitzenmaier J (2006) Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic treatment and metastases. Lancet Oncol 7(5):425-430. doi:10.1016/S1470-2045(06)70694-5
41. Bastin ME, Delgado M, Whittle IR, Cannon J, Wardlaw JM (1999) The use of diffusion tensor imaging in quantifying the effect of dexamethasone on brain tumours. Neuroreport 10(7): 1385-1391 (Pubitemid 29354317)
42. Minamikawa S, Kono K, Nakayama K, Yokote H, Tashiro T, Nishio A et al (2004) Glucocorticoid treatment of brain tumor patients: changes of apparent diffusion coefficient values measured by MR diffusion imaging. Neuroradiology 46(10):805-811. doi:10.1007/s00234-004-1268-1 (Pubitemid 39534607)
43. Armitage PA, Schwindack C, Bastin ME, Whittle IR (2007) Quantitative assessment of intracranial tumor response to dexa-methasone using diffusion, perfusion and permeability magnetic resonance imaging. Magn Reson Imag 25(3):303-310. doi: 10.1016/j.mri.2006.09.002 (Pubitemid 46413642)
44. Crokart N, Jordan BF, Baudelet C, Cron GO, Hotton J, Radermacher K et al. (2007) Glucocorticoids modulate tumor radiation response through a decrease in tumor oxygen consumption. Clin Cancer Res 13(2 Pt 1):630-635. doi:10.1158/1078-0432. CCR-06-0802 (Pubitemid 46225370)
45. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A et al (2005) The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 92(9):1599-1610. doi:10.1038/sj.bjc.6602550 (Pubitemid 40756468)
46. Sevick EM, Jain RK (1989) Geometric resistance to blood flow in solid tumors perfused ex vivo: effects of tumor size and perfusion pressure. Cancer Res 49(13):3506-3512 (Pubitemid 19178166)
47. Donaldson SB, West CML, Davidson SE, Carrington BM, Hutchison G, Jones AP, Sourbron SP, Buckley DL (2010) A comparison of tracer kinetic models for T1-weighted dynamic contrast-enhanced MRI: application in carcinoma of the cervix. Magn Reson Med 63(3):691-700. doi:10.1002/mrm.22217
48. Henderson E, Rutt BK, Lee TY (1998) Temporal sampling requirements for the tracer kinetics modeling of breast disease. Magn Reson Imag 16(9):1057-1073. doi:10.1016/S0730-725X(98)00130-1 (Pubitemid 29196842)
49. Henderson E, Sykes J, Drost D, Weinmann HJ, Rutt BK, Lee TY (2000) Simultaneous MRI measurement of blood flow, blood volume, and capillary permeability in mammary tumors using two different contrast agents. J Magn Reson Imag 12(6): 991-1003